Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 4/20 | 0.56 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | FFAR3 | O14843 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | PDE4A | P27815 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.36 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.36 |
| ▸ | AKR1A1 | P14550 | 1/20 | 0.36 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.36 |
| ▸ | HTR2A | P28223 | 1/20 | 0.36 |
| ▸ | HTR2C | P28335 | 1/20 | 0.36 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.36 |
| ▸ | HRH1 | P35367 | 1/20 | 0.36 |
| ▸ | DRD3 | P35462 | 1/20 | 0.36 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.36 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.36 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.36 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | GPR84 | Q9NQS5 | 3/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9965104 | 0.84 | TSHR (0.56) | TSHRCYP2C9FFAR3TP53PDE4A | |
| SCHEMBL8507977 | 0.84 | TSHR (0.56) | TSHRCYP2C9FFAR3TP53PDE4A | |
| Cadaverine Tartrate SCHEMBL1468444 | 0.82 | TSHR (0.62) | TSHRCYP2C9FFAR3TP53PDE4A | |
| Cadaverine Tartrate SCHEMBL18987140 | 0.82 | TSHR (0.71) | TSHRCYP2C9FFAR3TP53PDE4A | |
| Cadaverine Tartrate SCHEMBL28254283 | 0.80 | TSHR (0.59) | TSHRCYP2C9FFAR3TP53PDE4A | |
| Tartaric Acid SCHEMBL30771976 | 0.79 | TSHR (0.67) | TSHRCYP2C9FFAR3TP53PDE4A | |
| Cadaverine Tartrate SCHEMBL2158124 | 0.79 | TSHR (0.67) | TSHRCYP2C9FFAR3TP53PDE4A | |
| Cadaverine Tartrate SCHEMBL282045 | 0.79 | TSHR (0.67) | TSHRCYP2C9FFAR3TP53PDE4A | |
| Cadaverine Tartrate SCHEMBL7264826 | 0.78 | TSHR (0.56) | TSHRCYP2C9FFAR3TP53PDE4A | |
| Cadaverine Tartrate SCHEMBL27464873 | 0.78 | TSHR (0.56) | TSHRCYP2C9FFAR3TP53PDE4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2771003-B1 | BILE ACID RECYCLING INHIBITORS FOR TREATMENT OF PEDIATRIC CHOLESTATIC LIVER DISEASES | LUMENA PHARMACEUTICALS LLC (US) | 2017-04-19 | — | — | EP | disclosed |
| US-9458192-B1 | Covalent granzyme B inhibitors | VIDA THERAPEUTICS INC. (CA) | 2016-10-04 | — | — | US | disclosed |
| US-20130059807-A1 | BILE ACID RECYCLING INHIBITORS AND SATIOGENS FOR TREATMENT OF DIABETES, OBESITY, AND INFLAMMATORY GASTROINTESTINAL CONDITIONS | SATIOGEN PHARMACEUTICALS, INC. (US) | 2013-03-07 | — | — | US | disclosed |
| US-20130034536-A1 | Bile Acid Recycling Inhibitors for Treatment of Pancreatitis | Lumena Pharmaceuticals, Inc. (US) | 2013-02-07 | — | — | US | disclosed |
| US-20120157399-A1 | BILE ACID RECYCLING INHIBITORS FOR TREATMENT OF OBESITY AND DIABETES | SATIOGEN PHARMACEUTICALS, INC. (US) | 2012-06-21 | — | — | US | disclosed |
| US-20100130472-A1 | BILE ACID RECYCLING INHIBITORS FOR TREATMENT OF OBESITY AND DIABETES | SATIOGEN PHARMACEUTICALS, INC. (US) | 2010-05-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120157399-A1 | BILE ACID RECYCLING INHIBITORS FOR TREATMENT OF OBESITY AND DIABETES | SLC10A1, SLC10A2, ABCB11 | TSHR 1089/4885CYP2C9 1684/4885FFAR3 491/4885 |
| US-20130059807-A1 | BILE ACID RECYCLING INHIBITORS AND SATIOGENS FOR TREATMENT OF DIABETES, OBESITY, AND INFLAMMATORY GASTROINTESTINAL CONDITIONS | SLC10A2, GPR119, GPBAR1 | TSHR 968/4885CYP2C9 3391/4885FFAR3 166/4885 |
| US-20130034536-A1 | Bile Acid Recycling Inhibitors for Treatment of Pancreatitis | SLC10A2, SLC10A1, NR1H4 | TSHR 297/4885CYP2C9 4523/4885FFAR3 147/4885 |
| US-20100130472-A1 | BILE ACID RECYCLING INHIBITORS FOR TREATMENT OF OBESITY AND DIABETES | SLC10A1, SLC10A2, ABCB11 | TSHR 1089/4885CYP2C9 1684/4885FFAR3 491/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.